12:00 AM
Jul 22, 2013
 |  BC Week In Review  |  Clinical News  |  Clinical Status

OGX-427: Completed Phase II enrollment

OncoGenex completed enrollment of about 180 patients in the double-blind, placebo-controlled, international Phase II Borealis-1 trial comparing OGX-427 plus gemcitabine and cisplatin vs. gemcitabine and cisplatin alone. The trial is enrolling patients who have not received prior chemotherapy for metastatic disease and who are not...

Read the full 203 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >